## Biocon Limited (BIOCON) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Biocon Limited (BIOCON) is a leading Indian pharmaceutical company operating in the Pharmaceuticals industry.  Listed on the NSE on April 7, 2004, Biocon is a significant player in the sector, known for its research and development capabilities and diverse product portfolio.  The company's focus areas include biosimilars, research services, and generic formulations.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹336.00        | Closed at ₹335.95, down ₹14.35 from the previous close.             |
| Percentage Change (PChange) | -4.10%         | Significant negative daily change.                                   |
| Pre-Open Activity          | Mixed           | Pre-open prices showed some buying interest but ultimately closed lower. |
| Week High                    | ₹395.80        | High price reached during the week.                                  |
| Week Low                     | ₹239.30        | Low price reached during the week, indicating significant volatility. |
| VWAP                        | ₹340.48        | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 22.95          | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 22.23          | Price-to-Earnings ratio for Biocon.                                 |
| Delivery Percentage         | 45.04%         | Relatively high delivery percentage suggests some underlying strength. |
| Market Depth                | Low             | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The following table summarizes Biocon's financial performance over the past five quarters.  Note that the data provided is a mix of audited and unaudited figures.  Further analysis would require access to complete audited financial statements.

| Quarter Ending      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | Diluted EPS (₹) |
|----------------------|--------------|--------------|-----------------------|-----------------|
| 30-Sep-2024 (U)     | 59,890       | 57,800       | 320                   | 0.03            |
| 30-Jun-2024 (U)     | 55,250       | 55,140       | 90                    | 0.01            |
| 31-Mar-2024 (A)     | 57,150       | 54,970       | 1,400                 | 0.12            |
| 31-Dec-2023 (U)     | 61,130       | 57,840       | 2,400                 | 0.20            |
| 30-Sep-2023 (U)     | 58,830       | 53,710       | 3,470                 | 0.29            |

**(U) - Unaudited; (A) - Audited**

* **Trend:**  Profitability shows significant fluctuation, with a decline in the last two quarters.  Revenue growth is also inconsistent.  More detailed analysis is needed to understand the drivers of these fluctuations.  Key financial ratios (like ROA, ROE, Debt-to-Equity) are missing and would be crucial for a complete assessment.

**4. Corporate Actions and Announcements:**

Biocon has a history of declaring dividends and implementing bonus issues.  Recent corporate actions include a dividend of ₹0.50 per share with an ex-date of July 5, 2024.  Numerous recent announcements relate to analyst meetings and updates, suggesting active investor engagement.  However, the nature of these updates is not detailed enough for a comprehensive assessment.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|-----------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023     | 60.64%                     | 38.97% | 0.39%                         | 100.00%|
| 31-Dec-2023     | 60.64%                     | 39.03% | 0.33%                         | 100.00%|
| 31-Mar-2024     | 60.64%                     | 39.05% | 0.32%                         | 100.00%|
| 30-Jun-2024     | 60.64%                     | 39.08% | 0.28%                         | 100.00%|
| 30-Sep-2024     | 60.64%                     | 39.12% | 0.25%                         | 100.00%|

* **Trend:** Promoter holding remains stable, while public shareholding shows a slight upward trend.  The decrease in employee trust shareholding is minimal and doesn't seem significant.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low prices.  The low market depth further amplifies this risk.  The provided CM Daily and Annual Volatility (2.17% and 41.46% respectively) confirm this high volatility.  A thorough risk assessment requires additional data, such as beta and standard deviation.

**7. Advantages of Buying the Stock:**

* Relatively high delivery percentage in recent trading.
* Consistent promoter holding.
* Established player in the Pharmaceuticals sector.

**8. Disadvantages and Risks:**

* High volatility and low market depth.
* Inconsistent financial performance in recent quarters.
* Lack of key financial ratios for a complete assessment.
* Reliance on unaudited financial data for recent quarters.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The current price shows a significant negative trend, high volatility, and low market depth make short-term trading risky.
* **Medium-term (3 to 12 months): Hold (if you have stock).**  The medium-term outlook depends on improved financial performance and clarity on recent announcements.  Further monitoring is necessary.
* **Long-term (1 year and beyond): Hold (if you have stock).** Biocon's position in the pharmaceuticals sector offers long-term potential, but consistent financial performance and improved transparency are crucial for a positive long-term outlook.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health: 4/10 (Inconsistent profitability, missing key ratios)
* Market Performance: 3/10 (High volatility, negative recent price trend)
* Volatility and Risk: 2/10 (High volatility, low market depth)
* Corporate Actions & Governance: 7/10 (Consistent dividend history, active investor communication)
* Shareholding Patterns: 8/10 (Stable promoter holding)

**Analysis Score (out of 10): 7/10**

* Completeness and Data Utilization: 8/10 (Most data used, but some crucial information missing)
* Accuracy and Clarity: 7/10 (Analysis is clear, but limited by data availability)
* Professional Formatting: 8/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data, Biocon's short-term outlook is negative due to high volatility and inconsistent financial performance.  The medium-term and long-term outlooks are contingent on improved financial results and clarity regarding recent announcements.  Investors should closely monitor the company's performance and news before making any investment decisions.  A more comprehensive analysis would require access to complete audited financial statements and detailed information on recent announcements.
